Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai-Hong Kong Zhongke

Request full access

A one-stop pre-clinical CRO established by a full-time entrepreneurial team of the core team

ChinaFounded 2019Health Tech & Medtech

About Shanghai-Hong Kong Zhongke

Shanghai-Hong Kong Zhongke International Biotechnology Co., Ltd. (ZSHK Laboratories) operates as a preclinical contract research organization (CRO) servicing the biopharmaceutical industry. Founded in 2019, the company is headquartered in Hong Kong with its origins tracing back to the Safety Assessment and Research Center of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The core team possesses over two decades of experience in drug safety evaluation.

The company's business model is centered on providing a comprehensive, one-stop platform for preclinical research and development services to a global client base of pharmaceutical companies and R&D institutions. This service-based revenue model encompasses a suite of offerings critical for drug and medical device development. Key services include pharmacology and pharmacodynamics research, drug metabolism and pharmacokinetic (DMPK) studies, and comprehensive safety evaluations. By managing these essential preclinical stages, ZSHK enables its clients to advance their products through the regulatory pipeline.

ZSHK has established a significant operational footprint with independent laboratory facilities in strategic locations, including the Hong Kong Science Park, Pingshan District in Shenzhen, and the Suzhou Industrial Park in Jiangsu. This network of labs is complemented by a strategic focus on the supply chain for research models; the company has developed breeding and research bases for experimental canines and non-human primates in Hunan and Guangxi. The company has received multiple rounds of venture capital funding, including a Series B round in November 2022, to support its expansion.

The firm's service portfolio is extensive, covering early screening, pharmacodynamics, pharmacokinetics, and toxicity prediction. It offers specialized services such as histopathology research and laboratory testing and analysis. ZSHK also provides robust support platforms, including advanced IT and computerized systems designed for data security, a comprehensive instrument management system compliant with international regulations (NMPA, OECD, FDA), and a sophisticated document management system to support multinational applications. A subsidiary, AnLing Biomed (Shenzhen) Co., Ltd., achieved GLP certification from the NMPA in April 2023, a key milestone indicating adherence to quality standards for non-clinical laboratory studies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
4
Open positions
None listed
Dealroom signal
31.6/100
Industry
Health
Sub-industry
Health Platform
Sector
Hard Tech
Business model
SaaS
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Nov 2022 $14M $55M Ascendum Capital · AstraZeneca Pharmaceutical ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai-Hong Kong Zhongke website traffic

Latest recorded traffic for Shanghai-Hong Kong Zhongke is 710 monthly website visits, up 20.3% over the last three months. Shanghai-Hong Kong Zhongke's team grew 0% over the past year.

Latest monthly visits710 3-month web change+20.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shanghai-Hong Kong Zhongke in its local ecosystem

Live from Dealroom

The Shanghai-Hong Kong Zhongke office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Ascendum Capital
  • AstraZeneca Pharmaceutical
Employees 4 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇭🇰 Hong Kong100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai-Hong Kong Zhongke on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai-Hong Kong Zhongke’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.